PTGX Q2 2020 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+175.9% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$18M-293.0% margin

Net Income

-$19M-312.4% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+70.5%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$225M

Total Liabilities

$57M

Stockholders' Equity

$167M

Cash & Equivalents

$146M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	-$8M	+175.9%
Gross Profit	$6M	-$11M	+156.7%
Operating Income	-$18M	-$31M	+42.0%
Net Income	-$19M	-$29M	+33.4%

Revenue Segments

License And Collaborative Revenue

$114M100%

Financial Service Other

$500,0000%